Stock BLAU3 BLAU FARMACÊUTICA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Blau Farmacêutica S.A.

Equities

BLAU3

BRBLAUACNOR8

Delayed Sao Paulo
Other stock markets
 15:23:36 26/06/2024 BST 		5-day change 1st Jan Change
9.69 BRL -6.25% Intraday chart for Blau Farmacêutica S.A. +0.83% -40.77%
05-08 Transcript : Blau Farmacêutica S.A., Q1 2024 Earnings Call, May 08, 2024
05-07 Blau Farmacêutica S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company returns high margins, thereby supporting business profitability.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company has a low valuation given the cash flows generated by its activity.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Most analysts recommend that the stock should be sold or reduced.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BLAU FARMACÊUTICA S.A. Stock Blau Farmacêutica S.A.
-40.77% 317M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.24% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+45.31% 654B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.72% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.56% 337B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.12% 302B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.75% 247B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 229B
A+
NOVARTIS AG Stock Novartis AG
+12.91% 219B
B-
AMGEN INC. Stock Amgen Inc.
+9.80% 171B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BLAU3 Stock
  4. Ratings Blau Farmacêutica S.A.